Loading institutional data...
Loading institutional data...
Institutional accumulation: ownership increased +0.73% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $18.44 today, the market must believe free cash flow compounds 7.6%/yr for a decade (off $17M normalized FCF).
The market's 7.6% is more conservative than its 9-yr track record.
2-stage DCF · 0.02B shares · net debt -$31M
mean 18.1% · volatility σ 31% · implied rate exceeded in 6/9 yrs
Central path = implied 7.6%/yr growth; shaded band = ±1σ (31%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
5/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $17M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -52%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Interest last disclosed in FY2021 (no longer broken out).
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-18
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 26.9 | 26.6 | 25.6 | 22.8 | 20.1 | 19.5 | 38.4 | 41.6 |
| Gross Profit | 73.1 | 73.4 | 74.4 | 77.2 | 79.9 | 80.5 | 61.6 | 58.4 |
| R&D | 6.0 | 7.4 | 7.2 | 8.7 | 6.0 | 7.6 | 8.2 | 8.7 |
| SG&A | 32.3 | 34.7 | 39.3 | 44.3 | 37.3 | 46.4 | 31.9 | 26.4 |
| Operating Income | 34.7 | 31.3 | 27.9 | 24.2 | 27.7 | 14.6 | 8.8 | -89.3 |
| Income Tax | 4.1 | 5.8 | 4.9 | 2.8 | 4.9 | 2.9 | 3.5 | -5.9 |
| Net Income | 30.1 | 25.3 | 22.4 | 21.1 | 23.2 | 16.7 | 14.2 | -81.7 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on SLP: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-18
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $79.2M 100.0% | $70.0M 100.0% | $59.6M 100.0% | $53.9M 100.0% | $46.5M 100.0% | $41.6M 100.0% | $34.0M 100.0% | $29.7M 100.0% | $24.1M 100.0% | $20.0M 100.0% |
| Cost of Revenue | $33.0M 41.6% | $26.9M 38.4% | $11.6M 19.5% | $10.8M 20.1% | $10.6M 22.8% | $10.6M 25.6% | $9.0M 26.6% | $8.0M 26.9% | $6.3M 26.1% | $4.6M 23.0% |
| Gross Profit | $46.2M 58.4% | $43.2M 61.6% | $47.9M 80.5% | $43.1M 79.9% | $35.9M 77.2% | $30.9M 74.4% | $24.9M 73.4% | $21.7M 73.1% | $17.8M 73.9% | $15.4M 77.0% |
| Research & Development | $6.9M 8.7% | $5.8M 8.2% | $4.5M 7.6% | $3.2M 6.0% | $4.0M 8.7% | $3.0M 7.2% | $2.5M 7.4% | $1.8M 6.0% | $1.4M 5.7% | $1.4M 7.2% |
| Selling, General & Admin | $20.9M 26.4% | $22.4M 31.9% | $27.7M 46.4% | $20.1M 37.3% | $20.6M 44.3% | $16.4M 39.3% | $11.8M 34.7% | $9.6M 32.3% | $8.2M 34.0% | $6.7M 33.5% |
| Total Operating Expenses | $117.0M 147.7% | $37.0M 52.9% | $39.2M 65.8% | $28.2M 52.3% | $24.6M 53.0% | $19.3M 46.5% | $14.3M 42.1% | $11.4M 38.3% | $9.6M 39.6% | $8.1M 40.8% |
| Operating Income | -$70.7M -89.3% | $6.1M 8.8% | $8.7M 14.6% | $14.9M 27.7% | $11.3M 24.2% | $11.6M 27.9% | $10.6M 31.3% | $10.3M 34.7% | $8.3M 34.2% | $7.2M 36.2% |
| Interest Expense | — | — | — | — | $22K 0.0% | $0 0.0% | $0 0.0% | $153K 0.5% | $38K 0.2% | $0 0.0% |
| Interest & Investment Income | $722K 0.9% | $4.4M 6.2% | $4.1M 6.9% | — | — | — | — | — | — | — |
| Other Income (Expense), net | $1.4M 1.7% | $6.3M 9.0% | $3.0M 5.0% | $204K 0.4% | -$168K -0.4% | -$218K -0.5% | -$92K -0.3% | -$159K -0.5% | -$24K -0.1% | $5K 0.0% |
| Pretax Income | -$69.4M -87.6% | $12.4M 17.7% | $11.7M 19.6% | $15.1M 28.0% | $11.1M 23.9% | $11.4M 27.4% | $10.6M 31.1% | $10.1M 34.2% | $8.2M 34.1% | $7.2M 36.2% |
| Income Tax Expense | -$4.7M -5.9% | $2.5M 3.5% | $1.7M 2.9% | $2.6M 4.9% | $1.3M 2.8% | $2.1M 4.9% | $2.0M 5.8% | $1.2M 4.1% | $2.5M 10.2% | $2.3M 11.4% |
| Net Income | -$64.7M -81.7% | $10.0M 14.2% | $10.0M 16.7% | $12.5M 23.2% | $9.8M 21.1% | $9.3M 22.4% | $8.6M 25.3% | $8.9M 30.1% | $5.8M 24.0% | $5.0M 24.8% |
| Per Share | ||||||||||
| EPS (Basic) | $-3.22 | $0.50 | $0.50 | $0.62 | $0.49 | $0.52 | $0.49 | $0.52 | $0.34 | $0.29 |
| EPS (Diluted) | $-3.22 | $0.49 | $0.49 | $0.60 | $0.47 | $0.50 | $0.48 | $0.50 | $0.33 | $0.29 |
| Weighted Avg Shares (Basic) | 20.1M | 20.0M | 20.1M | 20.2M | 20.0M | 17.8M | 17.5M | 17.3M | 17.2M | 17.0M |
| Weighted Avg Shares (Diluted) | 20.1M | 20.3M | 20.5M | 20.7M | 20.7M | 18.5M | 18.1M | 17.9M | 17.5M | 17.2M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $829.3B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.0B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $466.9B | 111.8× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $367.5B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $341.5B | 28.5× | 19.8× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $245.6B | 36.7× | 31.7× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $207.8B | 27.1× | 17.8× | 5.7× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $186.3B | 22.1× | 20.3× | 6.3× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.6B | 27.6× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.2B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $149.7B | 41.9× | 30.9× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $139.7B | 50.0× | 38.4× | 13.9× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $129.1B | 33.2× | 28.3× | 10.8× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $128.3B | 18.2× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $117.9B | 24.7× | 12.5× | 3.2× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $112.9B | 63.9× | 11.3× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $105.2B | 32.8× | 18.1× | 4.2× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.0B | 22.8× | 16.1× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.1B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $90.7B | 16.3× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.1B | 18.9× | 19.6× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.5B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| SLP | $371M | — | — | 4.7× | 13.1% | 58.4% | -81.7% | -51.9% | -51.9% | — | 154 |
Peers = companies sharing SLP's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position